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Abstract: Staphylococcus aureus (S. aureus) is correlated with the
development of persistent severe inflammatory disease of the upper
airway including chronic rhinosinusitis with nasal polyps. This
inflammation of the upper airways is characterized by a T-helper
2–driven disease: interleukin-5 is significantly increased and local
production of immunoglobulin E is observed. S. aureus and its
enterotoxins are deregulating the tissue inflammation at different
levels: structural cells and the innate and adaptive immune system.
Knowing the triggers of the pathomechanisms involved will greatly
help us to find new therapeutic approaches to resolve this chronic
inflammatory process.
Key Words: chronic rhinosinusitis, nasal polyps, Staphylococcus
aureus, innate and adaptive immune system, superantigens
(WAO Journal 2010; 3:223–228)
INTRODUCTION
Chronic rhinosinusitis (CRS) is an inflammatory processof the nose and sinuses that is characterized by nasal
blockage/obstruction/congestion, nasal discharge, facial pain,
and /or reduction of smell.1 The diagnosis is based on symp-
toms and duration of the disease, nasal endoscopy, and CT
scan. Rhinosinusitis lasting less than 12 weeks is in most
cases of viral origin; however, it is currently unknown
whether recurrences of this process may lead to chronic
rhinosinusitis. CRS may be differentiated in CRS without
nasal polyps and with nasal polyps (CRSwNP), the latter
being characterized by a TH2-driven inflammatory process
with increased levels of interleukin (IL)-5, infiltration of
eosinophils, eosinophil cationic protein (ECP), and local
immunoglobulin (Ig)E production. In severe cases asthma
comorbidity and the presence of IgE against Staphylococcus
aureus (S. aureus) enterotoxins (SAE-IgE) is frequently
found.2 Colonization rates of S. aureus in healthy subjects
and patients with CRS have been found to be around 33.3 and
27.3%, respectively, whereas 63.6% of all subjects with
CRSwNP were colonized with S. aureus.3 By analysis of
biopsies of sinus mucosa from CRS patients, it was also
found that the presence of bacterial biofilm was increased
compared with control patients.4 Biofilms are formed when
bacteria adhere to surfaces in an aqueous environment and
begin to excrete a slimy, gluelike substance that can anchor
them to tissue. A biofilm can be formed by a single bacterial
species, but more often biofilms consist of multiple bacterial
strains. S. aureus is one of the bacteria frequently present in
biofilms within the nose, but it remains to be confirmed
whether biofilms via S. aureus carriage contribute to the
immune changes typical for nasal polyp disease.
S. AUREUS IN THE NOSE
The Gram-positive bacterium S. aureus is a major
pathogen in both community-acquired and nosocomial infec-
tions. S. aureus often colonizes the host asymptomatically
and lives as a commensal in the human nose. The anterior
nares are the major reservoir of S. aureus: 20% of the peoples
are persistently colonized and 60% are intermittent carriers,
whereas 20% never carry S. aureus.5,6 The anterior nares are
lined by a fully keratinized epidermis with hairs, sebaceous
glands, and sweat glands. The vestibule is limited above and
behind by a ridge, the limen nasi, over which the skin
becomes continuous with the nasal mucous membrane. Ap-
parently, the staphylococcal cells flourish here in the relative
absence of human defenses and/or are capable of withstand-
ing the local antibacterial defenses. To adhere, bacterial cells
need to establish firm interactions with human cell surfaces to
prevent their rapid elimination by physicochemical mecha-
nisms. To establish successful colonization, it is thought that
surface components of the staphylococcal cell interact with
complementary components on the eukaryotic host cell mem-
branes. Eukaryotic surface glycoproteins and proteoglycans
that are present on the mucous membranes contribute to the
adhesion of bacteria. S. aureus seem to adhere to mucin-
coated cells much better than to cells without such carbohy-
drate coating. Other substances like secretory immunoglob-
ulin A, glycolipids, and surfactant protein A may also
constitute receptor sites for S. aureus.7 S. aureus strains can
be divided into 4 major groups based on the accessory gene
regulator (agr) locus. This locus controls the expression of
most virulence factors, staphylococcal toxic shock syndrome
toxin-1 producing isolates belong to agr specificity group III,
and agr groups I and II are associated with enterotoxin-
mediated diseases. S. aureus enterotoxins (SAE) are potent
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molecules called superantigens8 that have the ability to si-
multaneously bind the invariant region of the MHC-II (major
histocompatibility complex, class II) molecules on antigen-
presenting cells and the T-cell receptor variable region 
(TCR-V).9 This leads to a potent activation and proliferation
of T cells, which induces the synthesis of IgE by B cells and
have direct effects on pro-inflammatory cells. In a study
published by Van Zele et al,10 it was found that 75% of the
strains present in human nasal mucosa produced at least one
enterotoxin. The enterotoxin gene cluster was observed in
67.5% of the strains, whereas the classic enterotoxins ap-
peared only in 42.5% of the strains. With use of the PNA
FISH method for the detection of intramucosal S. aureus in
healthy subjects and in patients with CRS, significantly more
S. aureus were observed in CRSwNP patients with aspirin-
exacerbated respiratory disease (AERD) versus controls and
CRS without nasal polyps.11
EFFECT OF S. AUREUS OR SAE ON THE INNATE
IMMUNE RESPONSE
Staphylococcal superantigens induce migration and
maturation of dendritic cell (DC) populations in vivo. How-
ever, in contrast to lipopolysaccharides, superantigens failed
to induce DC maturation in Recombination Activation Gene
(RAG) or MHC class II-deficient mice, suggesting that T-cell
activation was a prerequisite for DC maturation. The DC-
activating properties of T cells were confirmed by the anal-
ysis of in vivo responses to nonmicrobial T-cell mitogens,
suggesting that polyclonal activation of T cells in vivo may
lead to activation of the innate immune response.12 In an in
vitro model where human monocyte-derived DCs were stim-
ulated with S. aureus enterotoxin B (SEB), the authors
demonstrated that SEB induces the maturation of DCs and
initiates the secretion of high levels of IL-2 but not of
IL12p70. The SEB-induced maturation could be blocked
using anti–toll-like receptor 2 (TLR2) antibodies and anti–
nucleotide oligomerisation binding domain 1 (NOD1) anti-
body or RNA interference for these receptors.13,14 Further-
more, SEB-activated DCs were able to drive polarization of
naive T cells into the TH2 subsets by upregulation of T-cell
immunoglobulin mucin domain 4 (TIM4), as SEB-induced
DC could interact with TIM1 receptor on TH2 cells. Thus,
SEBs clearly shift DC to maturate and stimulate TH2 cells in
a TLR2-dependent manner. FACS analysis of the different
human DC subsets in CRSwNP tissue showed that the ratio of
mDC to pDC was significantly decreased15 compared with
control tissue and furthermore DCs were more mature in
CRSwNP (unpublished data). These findings suggest that
DCs are implicated in the development of CRSwNP but
further research is needed to clarify the direct impact of SAE
on DC.
Peptidoglycan (PGN), a major component of Gram-
positive bacteria cell walls and a potent activator of the
mammalian immune system, activates cells through NOD2,
PGN recognition proteins, and potentially TLR2/TLR6 het-
erodimers.16 PGN can also stimulate cells indirectly by acti-
vating complement products like C3a and C5a. Indeed, these
complement products are increased in nasal secretion of
people suffering from CRSwNP.17 C3a and C5a may induce
mast cell degranulation leading to the release of histamine,
and the activation of mast cells seems to be important for the
accumulation of DC from the lymph nodes.18
Not only DCs but also other innate immune cells such
as mast cells or macrophages in the upper airways are
activated by S. aureus or SEB. Mast cells are well-established
effectors in allergic airway inflammation. Cross-linking of
FcRI by IgE-bound inhaled antigen can trigger degranula-
tion defined by the release of the preformed secretory granule
complex and subsequent extracellular dissociation of pre-
formed mediators (eg, histamine and certain proteases). Ac-
tivation is accompanied by the rapid synthesis of lipid medi-
ators (eg, cys-LTs, dihydroxy leukotrienes, and prostaglandin
D2), and the induction of cytokines and chemokines (eg,
IL-4, IL-13, IL-12, IL-1, IL-18, and tumor necrosis factor-
[TNF-]). Mast cell mediator release can also be triggered by
innate signals, and innate mast cell activation can be part of
a protective immunity to pathogens.19 Mast cells may play an
important role in CRSwNP, as abundant degranulated mast
cells were observed in tissue sections. After S. aureus infec-
tion, mast cells increase the amount of TLR2 receptors on
their surface and consequently release of TNF- and IL-8.20
PGN, lipoproteins, and lipoteichoic acid from S. aureus are
able to stimulate mast cells directly via the binding of TLR2
on these cells. Short stimulation of nasal tissue explants with
Lipoteichoic Acid (LTA) or Surface Protein A (SPA) induced
a significant increase in mast cell mediators, including hista-
mine Leukotriene C4/D4/E4 (LTC4/D4/E4), and prostaglandin
D2 (PGD2).21 Macrophage mannose receptor, an innate pat-
tern recognizing receptor expressed by macrophages, is ca-
pable of phagocyte invaders (pathogens). The expression of
macrophage mannose receptor is significantly upregulated in
CRSwNP compared with turbinate tissue of controls.22 Re-
cent research by our group observed via immunohistochem-
istry and FACS analysis a significant upregulation of M2
macrophages in CRSwNP (unpublished data). S. aureus in-
hibits the production of superoxide in macrophages to evade
killing after phagocytosis; this mechanism is TLR2 mediat-
ed.23 Cumulatively, these findings suggest that S. aureus is
triggering a wide range of innate immune cells.
EFFECT OF S. AUREUS OR SAE ON THE
ADAPTIVE IMMUNE RESPONSE
Nasal polyps (CRSwNP) showed increased numbers
and activation of T cells, and an increase in plasma cells.
Additionally, significantly higher levels of eosinophilic mark-
ers (eosinophils, eotaxin, and ECP) together with a TH2
polarization with high IL-5 and IgE concentrations have been
found when compared with control nasal mucosa.24 Further-
more, CRSwNP is characterized by a low concentration of
transforming growth factor-1 (TGF-1), a downregulation
of FOXP3 (transcription factor for T regulatory cells) and on
transcriptional level with an upregulation of GATA-3 and
T-bet compared with control nasal mucosa.25 These results
suggest that TH2 cells are dominant and block the develop-
ment of T regulatory cells, or that there is a deficiency in T
regulatory cells which allows the TH2 cells to dominate as a
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consequence of the lack of counter regulation. We need to be
careful in generalizing this observation because nasal polyps
from Asian patients are also characterized by T-cell activa-
tion and impaired regulatory T-cell function. However, in
contrast to those from white patients, samples from Asian
counterparts demonstrated a TH1/Th17 polarization.26 So,
what is the difference between these patients: trigger? innate
response? Superantigens are shown to activate T cells and to
cross-link MHC-II on antigen-presenting cells and the T-cell
receptor variable region  chain on T cells. The observation
of IgE antibodies to SAE in nasal polyp tissue homogenates
demonstrated for the first time that these enterotoxins are
involved in the pathogenesis of nasal polyp disease.27,28
However, the prevalence of SAE-IgE formation differs be-
tween white (European) and Asian patients (unpublished
data). Furthermore, IgA and IgG concentrations were signif-
icantly higher in tissue homogenates, but not in serum, of
CRSwNP compared with CRS without nasal polyps and
control subjects. CRSwNP with specific IgE to SAEs showed
significantly higher concentrations of IgG and IgE antibodies,
and this goes together with an increase in plasma cells
(CD138) found in CRSwNP tissue. This suggests a local
production of these immunoglobulins in CRSwNP, likely in
response to a chronic microbial trigger.29 Furthermore, im-
munohistochemical staining for IgE, CD3, CD20, and CD138
demonstrated the presence of lymphoid accumulations and
follicle-like structures in nasal polyp tissue, which suggests
local IgE production.30 There is even evidence that compo-
nents (protein A) of the bacteria cell wall of S. aureus could
trigger B-cell activation directly.31,32 Stimulation of nasal
tissue explants originating from inferior turbinate or nasal
polyp tissue with the superantigen SEB for 24 hours stimu-
lated the release of TH1 and Th 2 cytokines (IFN-, IL-2,
IL-4, IL-5, IL-10, and IL-13). Furthermore, nasal polyp tissue
released more cytokines after stimulation compared with
control tissue.21
In a mouse model, our group recently observed that
SEB could facilitate the sensitization of CD4 cells to nasally
applied allergen, resulting in the development of experimen-
tal asthma. Treatment with anti-CD4 antibodies could abro-
gate the development of allergy. To evaluate the contribution
of DCs, nasal application of SEB was combined with FITC-
labeled ovalbumin (OVA) that was administered intratrache-
ally in the mice; DC migration toward the draining lymph
nodes was observed after 24 hours and the maturation
marker, CD86, was expressed at a higher level in OVA/SEB–
treated mice compared with OVA/saline–treated mice.33 Col-
lectively, these data suggest that SAEs have strong effects on
the proliferation of T cells.
EFFECT OF S. AUREUS OR SAE ON
NONIMMUNE CELLS
Histomorphologic analysis of nasal polyps showed the
presence of eosinophils, and the formation of a subepithelial
cap over a pseudocyst area that was filled with albumin.
TGF- plays a crucial role in airway inflammation and
remodeling. Furthermore, TGF- is considered a master
switch in the induction of the profibrotic program, and acts as
chemoattractant and proliferation factor for fibroblasts. In
CRSwNP the TGF-1 signaling pathway is strongly down-
regulated and this coincides with lower collagen content in
the polyp compared with control nasal mucosa.34 Does S.
aureus or SAE provoke changes in airway epithelial cells or
fibroblasts? The airway epithelium not only is a physiological
barrier but also actively is involved in the immune response
and a major source of inflammatory cytokines and mediators.
Nasal epithelial cells detect S. aureus through TLR2. The
nasal mucosa can also respond directly to bacterial challenge
through the elaboration of cationic polypeptides. Defensins
are such cationic antibacterial peptides and secreted by epi-
thelial cells. In humans 3  defensins (HBD1, HBD2, and
HBD3) are expressed; HBD2 has been shown to be upregu-
lated upon infection and can also be induced upon TLR2
activation and chemotactically attract neutrophil to the site of
infection. S. aureus and also other bacteria are capable of
upregulating TLR2 expression on epithelial cells; however,
when epithelial cells were exposed to S. aureus, TLR2
upregulation was delayed by 4 hours, and because of this
delay, the expression of HBD2 was prevented.35 Collectively,
these data suggest that S. aureus/SAE probably suppresses
the innate epithelial host response long enough to enable
colonization of the nasal mucosa. Not only the epithelial
cells but also the involvement of the fibroblasts in the
pathogenesis of airway disease is increasingly acknowl-
edged. Indeed, SEB challenge induced migration and
blocked proliferation of pretreated IFN- fibroblasts iso-
lated from inferior turbinate. IFN- was necessary to
induce the expression of MHC-II molecules.36 SEB treat-
ment of fibroblasts decreased the expression of cyclooxy-
genase-2 (COX-2) and prostaglandin E2 (PGE2). This
finding supports the idea that the presence of SEB may
induce airway inflammation by downregulating the pro-
duction of anti-inflammatory mediators.
ROLE OF S. AUREUS OR SAE IN THE
DEVELOPMENT OF ASTHMA AND AERD
The coexistence of asthma and CRS has been noted for
a long time; however, the debate remains as to whether CRS
is a risk factor for asthma. It seems that CRS and asthma are
linked by a common inflammatory pathway among which
eosinophils and airway epithelium play an important role. In
many patients with severe asthma, CRSwNP is common and
the presence of SAE has been recently identified as a possible
link between these 2 diseases, resulting in severe disease
manifestations in both upper and lower airways (unpublished
data). Surgical treatment of CRS or nasal polyposis might
improve asthma symptoms.37–39 Furthermore, a recent study
in teenagers proved the presence of IgE against SAE in atopic
subjects, which was associated with asthma risk.40
AERD is a clinical syndrome associated with chronic
severe inflammation in the upper and lower airways, resulting
in chronic rhinitis, sinusitis, recurrent polyposis, and severe
often difficult to control asthma.41 AERD has been generally
linked to abnormalities in the arachidonic acid biosynthetic
pathway where eosinophil infiltration in both upper and lower
airways constitute a key feature. However, the exact mecha-
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nisms of such chronic eosinophilic inflammation are not fully
understood. We have already shown that concentrations of
IgE antibodies to SAEs were significantly increased in pa-
tients with CRSwNP and AERD compared with controls and
CRSwNP without AERD. Furthermore, 54% of AERD pa-
tients demonstrated IgE antibody production against SAEs,
compared with 26% in the non-AERD and none in the control
groups. However, of interest, data from a subgroup analysis
for the criterium “IgE antibodies to SAEs” showed that
severity of inflammation is related to the presence of IgE to
SAE in the group of patients without AERD only.42 These
results were later confirmed by a study demonstrating the
increased presence of intracellular S. aureus in nasal polyps
from AERD patients compared with control nasal mucosa.11
Additionally, we demonstrated that nasal polyps of patients
with comorbid manifestation of asthma and AERD presented
a distinct systemic immune response to production and dif-
ferential expression of effector and T regulatory cell surface
markers. SEB induced a significantly higher release of
TNF- and IL-2 in nasal polyps from AERD patients after 4
hours of stimulation. In contrast, CRSwNP without AERD
and control subjects responded only with an increase of
IFN-. After 18 hours, SEB significantly induced the release
of TNF-, IFN-, IL-2, and IL-5 in both nasal polyp–asthma
groups compared with healthy controls but without statistical
differences between disease groups.43 All these data strongly
point to S. aureus colonization and production of superanti-
genic toxins as an important modifying factor of the inflam-
matory process operating in severe asthma and probably
AERD. Therefore, adequate management of bacterial infec-
tion may help with disease management and control in these
patients.
POSSIBILITIES TO COUNTERACT THE CHRONIC
INFLAMMATORY PROCESS INDUCED
BY S. AUREUS
The first-line treatment strategies of chronic inflamma-
tion of the upper airways consist of nasal corticosteroids and
antibiotics (with integrated anti-inflammatory activities).
Several clinical reports suggested that long-term, low-dose
macrolide antibiotics may be effective in treating CRS, which
is not curable via corticosteroid treatment.44 However, in a
double-blind placebo-controlled study the effects of methyl-
prednisolone (oral glucocorticoid) and doxycycline (antibi-
otic) were analyzed. Both significantly decreased nasal polyp
size compared with placebo; the effect of methylprednisolone
was maximal at week 2 and lasted until week 8, whereas the
effect of doxycycline was moderate but present for 12 weeks.
Methylprednisolone significantly reduced levels of ECP,
IL-5, and IgE in nasal secretions, whereas doxycycline sig-
nificantly reduced levels of myeloperoxidase, ECP, and
MMP-9 levels in nasal secretions.45 Antibiotics like doxycy-
clin have only some moderate effects probably because ma-
ture bacterial biofilms are able to resist antibiotic concentra-
tions up to 1000 times greater. This is because antibacterial
agents have difficulties in penetrating biofilms and killing
and/or inhibiting the proliferation of the bacteria within the
biofilm.46 Consequently, antibiotic therapies are generally
ineffective for the treatment of biofilm-associated bacterial
infections. In case of treatment failure, surgery is indicated.
Functional endoscopic sinus surgery (FESS) has become a
standard procedure to restore sinus ventilation and drainage
by opening the key areas. Symptomatic improvement for
nasal polyps after FESS is ranging from 37 to 99% (median
89%) with a 2 to 24% failure rate because of recurrence or
bad healing due to persistent inflammation and/or bacterial
colonization.47 Direct targeting of S. aureus is another option:
one possibility is via immunotherapy against S. aureus, which
is an attractive goal but until today there is currently nothing
available in the clinic.48 Another possibility is to make use of
the destructive effect of bacteriophages on their host organ-
isms, which has been exploited as a strategy for killing
infecting bacteria.49 Recently, the cell wall–degrading en-
zyme of siphoviridae bacteriophage 11 has been shown to
be capable of removing S. aureus biofilms and to possess
anti-Staphylococcal activity.50,51 However, effectiveness still
needs to be tested in clinical trials.
New therapeutic approaches are focusing on the knowl-
edge of the pathophysiology of nasal polyps: eosinophilic
inflammation, TH2 cells orchestrating the inflammatory pro-
cess, and the IgE antibodies produced locally. Anti-IL5 (resli-
zumab) is a candidate that was already tested in a double-
blind placebo-controlled clinical study and induced the
reduction of eosinophil numbers and concentration of ECP up
to 8 weeks after treatment. However, only the patients with
high nasal IL-5 concentration seemed to benefit from this
therapy.52 Another possibility that our group is evaluating is
the antagonism of IgE-mediated inflammation because in
CRSwNP a high correlation between IL-5 and IgE was found.
Superantigens produced locally in the airways may lead to
class switching of local B cells, resulting in polyclonal IgE
production in the airways and also specific IgE against the
superantigen. On the basis of these observations, anti-IgE
(Omalizumab) treatment could suppress the IgE-mediated
inflammatory cascade in nonallergic diseases such as
CRSwNP.53
CONCLUSION
Persistent inflammation of the airways is a disabling
disease with high morbidity, especially once asthma has
developed. A TH2-bias and S. aureus enterotoxins play an
important role in this inflammatory process. More thorough
knowledge regarding the impact of nasal pathogens on struc-
tural, innate, and adaptive immune cells is a prerequisite in
the process of unraveling the starting phase of the chronic
inflammatory process and might possibly help to develop
specific therapies.
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